



Universiteit
Leiden
The Netherlands

Guselkumab treatment normalizes the stratum corneum ceramide profile and alleviates barrier dysfunction in psoriasis: results of a randomized controlled trial

Rousel, J.; Mergen, C.; Bergmans, M.E.; Bruijnincx, L.J.; Kam, M.L. de; Klarenbeek, N.B.; ... ; Rissmann, R.

Citation






Rousel, J., Mergen, C., Bergmans, M. E., Bruijnincx, L. J., Kam, M. L. de, Klarenbeek, N. B., ... Rissmann, R. (2024). Guselkumab treatment normalizes the stratum corneum ceramide profile and alleviates barrier dysfunction in psoriasis: results of a randomized controlled trial. *Journal Of Lipid Research*, 65(8). doi:10.1016/j.jlr.2024.100591

Version: Publisher's Version
License: [Creative Commons CC BY 4.0 license](#)
Downloaded from: <https://hdl.handle.net/1887/4082379>


Note: To cite this publication please use the final published version (if applicable).



Guselkumab treatment normalizes the stratum corneum ceramide profile and alleviates barrier dysfunction in psoriasis: results of a randomized controlled trial

Jannik Rousel^{1,2,*}, Catherine Mergen^{2,*}, Menthe E. Bergmans^{1,3}, Lisa J. Bruijninx¹, Marieke L. de Kam¹, Naomi B. Klarenbeek¹, Tessa Niemeyer-van der Kolk¹, Martijn B. A. van Doorn^{1,4}, Joke A. Bouwstra², and Robert Rissmann^{1,2,3,*} on behalf of the Next-Generation ImmunoDermatology Consortium (NGID)

¹Centre for Human Drug Research, Leiden, The Netherlands; ²Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands; ³Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands; and the ⁴Department of Dermatology, Erasmus Medical Centre, Rotterdam, The Netherlands

Abstract The epidermal inflammation associated with psoriasis drives skin barrier perturbations. The skin barrier is primarily located in stratum corneum (SC). Its function depends on the SC lipid matrix of which ceramides constitute important components. Changes in the ceramide profile directly correlate to barrier function. In this study, we characterized the dynamics of the barrier function and ceramide profile of psoriatic skin during anti-Interleukin-23 therapy with guselkumab. We conducted a double-blind, randomized controlled trial in which 26 mild-to-severe plaque psoriasis patients were randomized 3:1–100 mg guselkumab or placebo for 16 weeks and barrier dynamics monitored throughout. Barrier function was measured by trans-epidermal water loss measurements. Untargeted ceramide profiling was performed using liquid chromatography-mass spectrometry after SC was harvested using tape-stripping. The barrier function and ceramide profile of lesional skin normalized to that of controls during treatment with guselkumab, but not placebo. This resulted in significant differences compared to placebo at the end of the treatment. Changes in the lesional ceramide profile during treatment correlated with barrier function and target lesion severity. Nonlesional skin remained similar throughout treatment.  Guselkumab therapy restored the skin barrier in psoriasis. Concomitant correlations between skin barrier function, the ceramide profile, and disease severity demonstrate their interdependency.

Supplementary key words Skin • Ceramides • Lipidomics • Clinical trials • Stratum Corneum • Psoriasis • Barrier

Psoriasis is a chronic inflammatory skin disease characterized by erythematous, indurated, and scaly lesions. Psoriasis can be increasingly well-managed in

clinical practice, but the presence of any residual lesions can still remain a significant burden to patients (1). While being primarily an immune-mediated inflammatory condition, cutaneous barrier perturbations allow exogenous substances to cross the skin barrier and enhance epidermal dysregulation (2). Indeed, barrier dysfunction is observed in lesional skin and, although not observed consistently throughout all studies, also in nonlesional skin (3–6).

Proper barrier function is in part regulated by the specific composition of ceramides present in the stratum corneum (SC) (7). Ceramides are incorporated in a highly organized lipid matrix together with mostly fatty acids and cholesterol (8). This matrix presents the only continuous penetration pathway for substances crossing the intact SC. The ceramide fraction is composed of many different ceramide species which can be categorized into as many as 25 different subclasses (Supplemental Fig. S1) (9). Alterations in the ceramide composition and concomitant decreases in skin barrier function have been observed in psoriasis and other inflammatory dermatological conditions (10). In atopic dermatitis (AD), these are correlated to barrier function (11–14). Additionally, *in vitro* studies have highlighted the potential of inflammation to affect the ceramide lipid biosynthesis and thereby aggravate barrier dysfunction (15, 16). Understanding barrier dysfunction in psoriasis might provide further insights into disease and prevent the formation of new lesions (17).

Pathomechanistic insights have identified the interleukin (IL)-23 and IL-17 axis as main driver of the aberrant immunological responses in psoriasis which enabled the development of effective targeted

ClinicalTrials.gov Listing: NCT04394936.

*These authors contributed equally to this work.

*For correspondence: Robert Rissmann, rissmann@chdr.nl.



immunosuppressing therapies (18). Guselkumab is an anti-IL23p19 monoclonal antibody that suppresses this pathway and has shown high and lasting effectivity in clinical practice (19, 20). Besides, its pronounced anti-inflammatory effect, anti-IL-23 therapy has shown to improve barrier function in a preclinical psoriasis mouse model where psoriatic lesions were induced using the toll-like receptor 7 agonist imiquimod (21).

Although studies have shown that the barrier function is decreased and the ceramide composition altered in lesional psoriasis, their longitudinal integration with measures for disease severity remains lacking and prevents the proper association of barrier dysfunction and lipid composition with disease (22–24). Therefore, we set out to investigate skin barrier dynamics in psoriasis by performing a randomized, placebo-controlled trial using guselkumab therapy in a cohort of 26 patients over 16 weeks of treatment. In-depth characterization of the ceramide profile in lesional and nonlesional skin was enabled by a comprehensive and untargeted lipidomic platform (25). Its repeated assessment and direct within-patient association to disease severity and barrier function will strongly position barrier dysfunction in psoriasis pathogenesis.

MATERIALS AND METHODS

Extended methods are present in the [supplementary information](#).

Study design

The SKINERGY-PP study was an investigator-initiated, exploratory, single-center, double-blinded, and placebo controlled randomized trial conducted from September 2020 to January 2023 at the Centre for Human Drug Research (Leiden, the Netherlands) and registered under NCT04394936. Ethical approval was obtained from the Medische Ethische Toetsings Commissie Brabant before study conduct commenced and adhered to the Declaration of Helsinki principles. The study included plaque psoriasis patients that were not undergoing active treatment, or with appropriate wash-out, and had at least one active lesion of sufficient size to allow for sampling and with a minimal lesion severity score ≥ 6 . The use of medication prior and during the study was prohibited, including the application of any topical products on lesions subjected to assessment. Control subjects without any dermatological conditions and otherwise healthy were included and matched for average sex, age, and tape-stripping location to the patient group. A total of 26 patients were randomized 3:1 to subcutaneous injections at week 0, 4, and 12 with guselkumab 100 mg ($n = 20$) or placebo ($n = 6$), respectively. The full in and exclusion criteria, demographics of the study population, and locations of the assessments are presented in the supplementary information.

Clinical scoring of psoriasis severity

Severity was scored using the psoriasis area and severity index (PASI) (26). Additionally, the lesion severity score (LSS) of the target lesion was obtained by grading erythema, scaling,

and induration on a 5-point scale (0; clear – 4; severe) and summing these scores (27, 28).

Trans-epidermal water loss

Assessments were performed under controlled environmental conditions of $<60\%$ humidity and $22 \pm 2^\circ\text{C}$. Cutaneous water loss was determined using an AquaFlux AF200 (Biox Systems Ltd., London, United Kingdom) over 180 s or until steady state was reached.

Tape-stripping and ceramide lipidomics

Subsequently, a total of eight tapes (Nichiban, Tokyo, Japan) were pressed onto the skin using a D500-pressure instrument (D-squame, Cuderm Corporation, Dallas, TX) of which tape 5–8 were used for analysis. A 16 mm diameter circle was punched out and stored in chloroform:methanol (2:1) awaiting extraction. Tapes were extracted using a modified 4-step Bligh and Dyer extraction at elevated temperature as described by Boiten *et al.* (2016) (25). Extracts from tape strips 5–8 were pooled for analysis. Lipidomics was performed using liquid chromatography-mass spectrometry as described in the supplemental materials.

Statistics

Statistical testing for the subclass profile was performed in comparison to baseline using a mixed-effect model with the Geisser-Greenhouse correction and Bonferroni correction for multiple comparisons in Prism 9.0 (GraphPad, Software, Boston). Comparisons between Guselkumab and placebo were performed within a mixed effects model with treatment and time and treatment by time as fixed factors and subject as random factor in SAS 9.4 (SAS Institute Inc., Cary, NC). Repeated measures correlation was performed using Rmcorr in R Statistical Software (version 4.1.2, R Core Team 2021) (29). (Change in) Mean and 95% confidence intervals (95%CI) are reported. Statistical significance is shown as follows: $P \geq 0.05$: ns, $P < 0.05$: *, $P < 0.01$: ** and $P < 0.001$: ***.

RESULTS

A total of 26 patients with plaque psoriasis and 10 healthy controls were included in the study (Supplemental Fig. S2). Demographics are listed in Supplemental Table S1 and the adverse events associated with guselkumab or placebo treatment have been reported previously (30, 31).

Guselkumab therapy is effective and normalized the skin barrier function

Effective disease remission was induced in the guselkumab group, as the plaque that was subjected to all assessments showed a significant reduction in local LSS compared to placebo throughout 16 weeks of treatment (1.20, 95%CI [0.43, 1.97] vs. 6.33 95%CI [3.62, 9.04], $P < 0.001$) (Fig. 1). In parallel, the whole-body PASI score decreased significantly compared to placebo (0.91, 95%CI [0.46, 1.36] vs. 5.86, 95%CI [12.13, –0.40], $P < 0.001$) (Supplemental Fig. S3). Complete skin clearance was not obtained since PASI and LSS scores were >0 after 16 weeks of guselkumab treatment.




Fig. 1. Clinical severity and barrier function during treatment with guselkumab ($n = 20$) or placebo ($n = 6$). The local severity at the target plaque subjected to assessments in this study is determined using the Lesion Severity Score (A). Barrier function as determined by trans-epidermal water loss (TEWL) was determined for both lesional and nonlesional skin (B). No significant difference was observed over time for nonlesional skin. Graphs represent the mean and 95% confidence interval. The dotted black line and gray band represent the mean and 95% confidence interval of the control group at baseline.

Skin barrier function was measured by trans-epidermal water loss (TEWL). TEWL in lesional skin decreased significantly during guselkumab treatment compared to placebo indicating a decrease in barrier dysfunction ($16.3 \text{ g/m}^2/\text{hours}$, 95%CI [12.1, 20.5] vs. $40.2 \text{ g/m}^2/\text{hours}$, 95%CI [17.12 63.3], $P < 0.001$). TEWL of lesional skin was comparable to that of nonlesional skin after 16 weeks of treatment ($11.5 \text{ g/m}^2/\text{hours}$, 95%CI [9.6, 13.3]) and controls ($15.5 \text{ g/m}^2/\text{hours}$, 95%CI [10.1, 21.0]). No significant changes in the TEWL of nonlesional skin over time were observed.

The ceramide profile normalizes during treatment with guselkumab but not placebo

After determining the skin barrier function, tape stripping was performed at the same site to obtain SC for analysis of the ceramide profile. No evident change in total ceramide content was observed (figure s4). However, a significant increase in the average abundance of Cer[NP] (2.059%, 95%CI [3.732, 0.3868], $P = 0.01$), Cer[NH] (2.737%, 95%CI [4.332, 1.142], $P = 0.001$), and Cer[AP] (2.524%, 95%CI [3.912, 1.136], $P < 0.001$) was observed compared to baseline already after 4 weeks of guselkumab treatment (Fig. 2). At 16 weeks, these abundances remained significantly increased (Cer[NP]; 9.074%, 95%CI [12.78, 5.366], $P < 0.001$, Cer[NH]; 2.999%, 95%CI [4.138, 1.859], $P < 0.001$, Cer[AP] 6.506%, 95%CI [8.356, 4.657], $P < 0.001$). The abundance of Cer[Ads] (1.958%, 95%CI [2.921, 0.9943], $P < 0.001$) and Cer[EOS] (1.38%, 95%CI [2.474, 0.2853], $P = 0.01$) were additionally significantly increased compared to baseline at 16 weeks. Contrarily, a significant decrease in the abundance of Cer[NS] (week 4: -4.674% , 95%CI [-8.013 , -1.335], $P = 0.006$, week 16: -15.71% , 95%CI [-19.69 , -11.72], $P < 0.001$) and Cer[AS] (week 4: -2.263% , 95%CI [-4.069 , -0.4564], $P = 0.01$, week 16: -10.72% , 95%CI [-13.02 , -8.419], $P < 0.001$) was observed from week 4 onwards. Although Cer[NdS] initially significantly

decreased at week 4 (-2.567% , 95%CI [-3.977 , -1.157], $P < 0.001$), this decrease was not maintained at 16 weeks (0.1143% , 95%CI [-2.375 , 2.146], $P > 0.99$). The abundance of ceramides from the Cer[O] fraction, as well as several Cer[EO] subclasses, was low in controls and was even further decreased in lesional psoriasis at baseline. Despite this, a treatment effect could be detected in the guselkumab group. The abundance of Cer[EOH] (0.3742%, 95%CI [0.7268, 0.02154], $P = 0.04$) and Cer[OH] (0.1005%, 95%CI [0.1953, 0.005718], $P = 0.04$) increased significantly after 4 weeks of treatment. Additionally, Cer[EOdS] (0.2104%, 95%CI [0.3801, 0.04069], $P = 0.01$), Cer[OS] (0.4892%, 95%CI [0.8398, 0.1387], $P = 0.006$), and Cer[EOS] (1.38%, 95%CI [2.474, 0.2853], $P = 0.01$) abundances significantly increased after 16 weeks of guselkumab treatment. No significant differences were observed in the abundances of Cer[AH], Cer[EOP], Cer[OdS], and Cer[OP] over time for the guselkumab group. In the placebo group, no significant changes compared to baseline were observed in the subclass profile at all. The actual amounts of the ceramide subclasses are shown in Supplemental Table S3.

In line with changes to the overall ceramide profile, specific ceramide parameters showed concurrent changes (Fig. 3). Increased abundances of Cer[NP] compared to Cer[NS] in the ceramide profile were reiterated based on a decreasing Cer[NS]:Cer[NP] ratio over time, which resulted in a significant decrease compared to placebo after 16 weeks of treatment (1.05 , 95%CI [0.70, 1.93] vs. 4.15 , 95%CI [3.13, 5.18], $P < 0.001$).

As Cer[NS] remains abundant in lesional and nonlesional skin, the degree of monounsaturated ceramides can be reliably detected without confounding resulting from decreases in overall Cer[NS] abundances (32). Therefore, the percentage monounsaturated Cer[NS] (MUCer[NS]) of Cer[NS] was used as an indicator of the degree of unsaturation. The fraction MUCer[NS] decreased significantly in the guselkumab group




Fig. 2. The ceramide subclass profile in lesional skin of psoriasis patients after 16 weeks of guselkumab or placebo treatment compared to controls at baseline. The ceramide subclass profile of the lesional skin of patients after 0, 4, and 16 weeks of guselkumab (n = 20) or placebo (n = 6) treatment. The ceramide profile of healthy controls (n = 10) determined during a single occasion is shown as reference. Note the different x-axis for the Cer[EO] and Cer[O] fraction because of their low abundance. Pairwise comparisons are only reported within treatment groups between baseline and week 4 or week 16.

compared to placebo from week 4 onwards (5.40%, 95% CI [3.09, 7.71], vs. 19.61%, 95%CI [15.59, 23.63], $P < 0.05$) and ultimately reached the level observed in controls after 16 weeks (guselkumab: 5.40%, 95%CI [3.09, 7.71], placebo: 19.61%, 95%CI [15.59, 23.63], $P < 0.001$, controls: 7.6%, 95%CI [5.4, 9.8]).

Constituting a very-short chain ceramide, the abundance of ceramide Cer[NS] with 34 total

carbons (Cer[NSc34]) decreased over time in the guselkumab group and reached statistical significant compared to placebo after 16 weeks of treatment (3.00%, 95%CI [1.96, 4.05] vs. 7.77%, 95%CI [5.97, 9.57], $P < 0.001$). However, its abundance at 16 weeks remained markedly higher than nonlesional (1.07%, 95%CI [0.59, 1.55]) and control skin (0.53%, 95%CI [0.31, 0.77]).




Fig. 3. The effect of guselkumab treatment on disease severity and ceramide parameters over time in subjects randomized to guselkumab (n = 20) or placebo (n = 6). Lesional and nonlesional skin is followed over time with ceramide profiling yielding the Cer [NS]:Cer[NP] ratio (A), percentage monounsaturated Cer[NS] (MUCer[NS]) of total Cer[NS] (B), percentage Cer[NSc34] of total Cer [NS] (C), and the average ceramide chain length (CCL) of the Cer[A] and Cer[N] fraction (D) as representative parameters of the altered ceramide profile at baseline. Graphs represent the mean and 95% confidence interval. The dotted black line and gray band represents the mean and 95% confidence interval of the control group at baseline. *P*-values are indicated when comparing lesional skin of the guselkumab group with the lesional skin of the placebo group. No statistically significant changes were present when comparing nonlesional skin in the placebo group with nonlesional skin in the guselkumab group.

Lastly, ceramide elongation was investigated. The detection of the individual and intact ceramides enables the determination of the ceramide chain length (CCL), defined as the total number of carbons within the molecule. The average CCL of Cer[N,A] (Cer[N,A]) showed a gradual increase throughout treatment with guselkumab, but not placebo. This increase was significant compared to placebo at both week 4 (42.84 carbons, 95%CI [42.49, 43.18] vs. 42.17 carbons, 95%CI [41.72, 42.61], $P < 0.05$) and week 16 (44.28 carbons, 95%CI [43.90, 44.66] vs. 41.93 carbons, 95%CI [41.50, 42.37], $P < 0.001$). Compared to the Cer [N,A] fraction, the CCL in the Cer[EO] fraction showed a smaller but still significant increase compared to placebo after 16 weeks of treatment (68.51 carbons, 95%CI [68.29, 68.73] vs. 67.92 carbons, 95%CI [67.52, 68.31], $P < 0.05$). No significant differences were observed compared to placebo for the CCL of Cer[O] at week 4 (49.83 carbons, 95%CI [49.61, 50.14] vs. 50.00 carbons, 95%CI [49.71, 50.29], $P = 0.87$) or week 16 (49.79 carbons, 95%CI [49.49, 50.08] vs. 49.91 carbons, 95%CI [49.31, 50.52], $P = 0.46$) (Supplemental Fig. S5). Of note, results were maintained when ceramides of CCL ≤ 34 were excluded from the

analysis (data not shown). When evaluating the aforementioned parameters in nonlesional skin, these remained consistent over time and were comparable to those observed in controls.

Integration of the complete saturated ceramide profile using dimension reduction analysis visualizes the conformity between different samples based on their proximity to each other. At baseline, samples of nonlesional skin of patients are overlapping with that of controls indicating similarity. However, the ceramide profile of lesional skin appears markedly different from both control skin and nonlesional skin (Fig. 4). The lesional profile starts shifting towards that of healthy volunteers already after 4 weeks of treatment. After 16 weeks, all lesional samples have become separated from those obtained at baseline and overlap fully with those from healthy controls and nonlesional skin, indicating a high degree of similarity between these samples. Of note, two samples obtained at week 16 remain closer to those of week 4 and 0 which indicates incomplete normalization. Listing of the loadings that drive the principal component analysis indicates that the abundance of Cer[NS], Cer[AS], and Cer[NP] with CCLs between 42 to 48 carbons, and to a lesser extent




Fig. 4. The ceramide profile of lesional skin during guselkumab treatment and the ceramide profile of nonlesional skin and healthy controls at baseline visualized by principal component analysis. The relative composition of all detected saturated ceramides is used for each data point in the PCA. Profiles of healthy controls are added as a reference for a normal ceramide profile. Additionally, the nonlesional skin of psoriasis patients at baseline (week 0) is included. A high proximity between data points indicates a high degree of similarity. The amount of variance explained per principal component (PC) is displayed on the axis.

those with 34 carbons, are the driving factors behind the distribution of datapoints (Supplemental Table S4).

Ceramide parameters correlate with barrier dysfunction and disease severity

The repeated assessment of disease severity, barrier function, and the ceramide profile during guselkumab treatment allows the establishment of a relationship between these parameters (Fig. 5). However, the repeated assessment of the same patient during the trial results in dependent data over time, which disqualifies the use of standard correlation analysis as this may lead to bias or wrongful results. Instead, repeated measures correlations are used as an alternative which is compatible with this dataset to determine the common within-individual association (29). Firstly, the local LSS and total-body PASI correlated strongly which indicates that both reflect the treatment response similarly ($r_{rm} = 0.90$). The relationship between LSS and the ceramide profile was strong with high correlation coefficients




Fig. 5. Correlation between disease severity and barrier function or ceramide parameters from patients receiving guselkumab treatment. Repeated measures correlation coefficients (r_{rm}) between local lesion severity (LSS) score, the psoriasis area and severity index (PASI) and trans-epidermal water loss (TEWL) are plotted. Additionally, the Cer[NS]:Cer[NP] ratio, monounsaturated Cer[NS] (MUCer[NS]), percentage Cer[NSc34], and the average ceramide chain length (CCL) of Cer[A] and Cer[N] are contrasted with the LSS. Lastly, these ceramide parameters are correlated with TEWL. Lines indicate the common within-individual association per subject and directly relate to the r_{rm} coefficient.

between LSS and the Cer[NS]:Cer[NP] ratio ($r_{\text{rm}} = 0.87$), abundance MUCer[NS] ($r_{\text{rm}} = 0.87$), Cer[NSc34] ($r_{\text{rm}} = 0.85$) and average CCL in Cer[N,A] ($r_{\text{rm}} = -0.88$). A significant correlation between barrier function measured by TEWL and LSS was observed ($r_{\text{rm}} = 0.60$). Additionally, barrier function correlated with the ceramide parameters as significant repeated measures correlations were observed between TEWL and Cer[NS]:Cer[NP] ratio ($r_{\text{rm}} = 0.64$), abundance MUCer[NS] ($r_{\text{rm}} = 0.58$), Cer[NSc34] ($r_{\text{rm}} = 0.65$) and average CCL in Cer[N,A] ($r_{\text{rm}} = -0.66$).

DISCUSSION

Here, we demonstrate the dynamics of barrier dysfunction and the ceramide profile as investigated during a prospective, randomized, placebo-controlled trial in psoriasis patients. Guselkumab treatment, but not placebo, normalized the full ceramide profile in lesional skin compared to that of controls thereby resolving barrier dysfunction. We show that changes in the ceramide profile correlate with both disease severity and barrier function.

Normalization of the ceramide profile during guselkumab treatment

The barrier function of the SC is heavily dependent on the ceramides of the extracellular lipid matrix (8). The ceramide profile of lesional psoriasis is altered with marked decreases in Cer[P] abundances and a lower CCL (23, 33–35). Additionally, the abundance of ceramides with a total chain length of 34 carbons is increased (23), as also observed in this study through higher Cer[NSc34] abundances. In this study, we demonstrate the normalization of the entire ceramide profile during treatment, including the increased abundance of MUCer[NS]. Increased unsaturation had been observed in Netherton syndrome, atopic dermatitis, and seborrheic dermatitis but had not yet been described in psoriasis (32, 36, 37).

Normalization of the balance between dihydroceramide desaturase (DES)–1 and –2 activity might explain the restored Cer[NS]:Cer[NP] ratio as they mediate the final step in Cer[S] and Cer[P] synthesis, respectively (38). DES-2 has shown to be downregulated in the SC of lesional AD (39). However, abundances of Cer[dS] and Cer[H] appear altered as well. This indicates a more upstream inhibition of ceramide synthesis as Cer[dS] is the precursor for Cer[P] (38). Indeed, a DES-2 KO model indicated other enzymes might differentially contribute to Cer[P] synthesis as Cer[P] was still present despite knocking out DES-2 (40). Rather, restoration of the impaired ceramide synthesis might relate to the restoration of proper epidermal homeostasis during treatment as skewing of the Cer[NS]:Cer[NP] ratio has been related to the aberrant overall epidermal hyperplasia typical of psoriasis (41). Increased unsaturation might result from an increase

in stearoyl-CoA-9-desaturase-1 activity, which mediates the rate-limiting step in monounsaturated fatty acid synthesis and therefore also monounsaturated ceramides (38, 42). The involvement of stearoyl-CoA-9-desaturase-1 in psoriasis has not been properly elucidated, but its expression was increased in AD (43). However, stearoyl-CoA-9-desaturase's upstream activators such as the liver-X receptor-alpha and sterol regulatory element binding protein-1 have previously been reported to be downregulated in lesional psoriasis instead, highlighting the need to specifically determine the expression or activity of stearoyl-CoA-9-desaturase-1 in psoriasis (44, 45).

Besides normalization of the subclass profile of lesional skin, impaired ceramide elongation is alleviated by evident increases in the CCL of Cer[N,A] and a more limited increase in the CCL of the Cer[EO] fraction. A psoriasis mouse model showed decreases in the expression of fatty acid elongases ELOVL1, ELOVL3, and ELOVL4 as well as ceramide synthase 3, which are all involved in the synthesis of ceramides exceeding 24 carbons (22). These findings are supported by studies in AD where comparable changes were observed in patients and after inducing inflammation in models (43, 46, 47). This reduction in CCL can be attributed to a decrease in the length of either the acyl chain, the sphingoid base, or both, as the length of both chains has been shown to be reduced in psoriasis (22, 48). Of note, the presence of short-chain Cer[NSc34] is increased in lesional skin as previously reported in AD, ichthyosis, and psoriasis (8, 10). These short-chain ceramides are involved in cellular stress responses and have been associated with inflammation and higher cardiovascular risk (49, 50). Their increased abundance in psoriatic skin, and subsequent decrease during guselkumab treatment, might therefore more aptly reflect the dysregulated homeostasis instead of changes to lipid elongation. However, normalization of lipid elongation might have further facilitated the decrease of Cer[NSc34] by effectively reducing the abundance of shorter fatty acids used as substrate in ceramide synthesis (38). This might differentially contribute to the decrease in cellular stress responses caused by this bioactive ceramide and aid in the normalization of ceramide synthesis altogether (51). The noninflammatory phenotype of uninvolved psoriasis is reiterated by a high similarity to healthy control skin as shown in this study (33, 52). This differentiates psoriasis from AD where nonlesional barrier defects are cemented in its pathogenesis (53). Ultimately, anti-IL-23 therapy is able to normalize the alterations in the SC ceramide profile which are associated with psoriasis and other dermatoses (10).

Barrier restoration during guselkumab treatment

Barrier dysfunction is evidently tied to lesional psoriasis (24, 54–56). Previous studies have demonstrated that TEWL of lesional skin improves after treatment in

line with clinical scores but did not monitor TEWL during treatment and correlate this directly to (local) disease severity (6, 57, 58). Here, guselkumab treatment effectively restores the barrier function of lesional skin in parallel with the clinical remission of disease. We expand on this by using a highly effective treatment contrasted with a placebo group and by performing repeated measures correlation analysis to further link disease severity to barrier dysfunction in lesional skin. TEWL values of nonlesional skin remained comparable with that of controls throughout the 16-weeks study indicating barrier impairment is limited to lesional skin, in contrast to what was observed in a smaller cross-sectional study (5).

The effect of guselkumab on barrier function and the ceramide profile

Guselkumab prevents the association of IL-23 with its receptor, preventing the activation of IL-17 producing cells. Significant decreases in clinical disease severity compared to placebo were expected based on its efficacy in phase III trials and real-world evidence (19, 20, 59). However, little is known about the direct impact of IL-23 on ceramide synthesis. IL-23 expression by keratinocytes has shown to result in enhanced interferon-gamma responses (60). This cytokine can directly impact SC ceramide synthesis with a pronounced effect on CCL (15, 16, 61). Additionally, induction of psoriatic lesions in mice using imiquimod has shown to result in barrier dysfunction which could be effectively reduced with anti-IL-12/23 therapy (21). Although imiquimod application has also shown to alter the ceramide profile, the potential to reverse these imiquimod-induced alterations with anti-IL-23 therapy has not yet been investigated (22). Conversely, it has been shown that knocking-out serine palmitoyltransferase in mice, causing a severe impairment of ceramide synthesis leading to a reduction in overall epidermal ceramides, spontaneously develop psoriatic-like lesions with increased TEWL which was treatable with IL-12/23 therapy (62). Tumor necrosis factor represents another, more upstream, therapeutic target for psoriasis (63). Supplementation of tumor necrosis factor resulted in alterations in the ceramide profile and expression of ceramide synthesis proteins of in vivo skin models (16, 64). This preclinical basis affirms the potential of guselkumab to influence barrier dysfunction through its upstream and downstream pro-inflammatory mediators as observed in this study.

Correlations

We performed a double-blind, randomized, placebo-controlled trial to solidly affirm the relationship between alterations in the ceramide profile, barrier dysfunction, and psoriasis. Previously, a smaller cross-sectional study linked barrier dysfunction to skewing of subclass ratios but did not consider disease severity (41). Another study showed barrier impairment with

concomitant alterations in the ceramide profile but did not evaluate direct, intra-patient correlations (24). We demonstrate that alterations in the ceramide composition, unsaturation, and CCL of lesional skin are paired with decreased barrier function throughout lesions with variable severity. Correlations between changes in ceramide composition and permeability have been demonstrated using model systems that mimic the lipid matrix of the inflamed skin where a decrease in barrier function was observed by skewing Cer[NS]:Cer[NP] (65, 66), decreasing CCL (67, 68), and increasing unsaturation (69). Moreover, the altered ceramide profile is implicated in the barrier impairment of in vitro-cultured human skin equivalents (70, 71). In AD and seborrheic dermatitis, alterations in the ceramide profile have provided a basis for the observed barrier dysfunction (32, 41, 72–74).

While the repeated measure correlation indicates a relationship between barrier function and ceramide profile, the correlation between LSS and the ceramide profile is stronger. Although the skin barrier is highly dependent on the ceramide profile, other factors might differentially contribute to skin barrier dysfunction in psoriasis (17). A stronger relationship between the ceramide profile and LSS might be explained by the fact that both reflect the extent of epidermal dysregulation which as this is directly assessed by clinical scoring but can also be linked to the ceramide profile (10, 41). Of note, the association between local severity and barrier parameters was affirmed by two patients who showed incomplete local remission despite a decrease in PASI score and maintained a ceramide profile closer to baseline despite receiving guselkumab. Therefore, we focused on the LSS rather than full body PASI to reflect local disease severity more accurately. However, correlations between PASI and LSS remained high indicating that both may be used.

Ceramide profiling as a biomarker for treatment monitoring

The relationship between treatment effect and ceramide profiles might allow for its exploitation as a biomarker. For instance, Cer[NSc34] constitutes a single biomarker that is able to discern lesional from nonlesional skin and gradually decreases during treatment. Traditional clinical endpoints, such as the observer-based physician global assessment and PASI scores, have become the gold standard but are associated with poor sensitivity, bias, and high interrater variability (26, 75, 76). Additionally, it remains a challenge to use traditional clinical endpoints in the scoring of mild psoriasis as also included in this study due to insensitivity (77, 78). Expanding clinical endpoints with objective measures might increase the value of these results (79).

Earlier, analysis of a limited amount of ceramides showed that increased Cer[NS] and decreased Cer[EOS] abundances in the skin of patients with AD normalized


towards the level of controls during dupilumab treatment (80, 81). Here, we show the same effect in psoriasis during effective treatment but extend it to the entire ceramide profile. Considering the similarity of the ceramide profile in psoriasis and AD, together with its comparable response to effective treatment, ceramide profiling might also be applied to other indications where similar alterations are observed such as ichthyosis (10). However, treatment responses of plaques within the patient might differ which should be considered when only selected lesions are monitored (82). Although TEWL and ceramides are both markers of skin barrier function, ceramide readouts from lesional skin seem less variable. TEWL can be impacted by personal factors, environmental factors, and differ between measurement locations (83, 84). Although these factors can also impact the ceramide profile, their influences might be more limited (85–89). Results obtained with tape stripping might vary depending on sampling depth as total ceramide abundances have been shown to be higher in deeper layers of the SC (90). This might be especially relevant in psoriasis considering the presence of hyperkeratosis with excessive scaling. However, the relative ceramide subclass composition has been reported to be comparable at varying SC depths up to 33 consecutive tape strips, indicating that compositional changes might be interpreted irrespective of sampling depth (25). Tape-stripping has already been applied to obtain protein and transcriptome-based biomarkers that are able to reflect the specific inflammatory component of specific diseases (91–93). In contrast to proteins, ceramides represent less proximal biomarkers that might be more primarily related to the general inflammatory status of the skin and the resulting aberrant epidermal differentiation (41). Although this disconnect might challenge its use as a diagnostic biomarker, the more general relationship between ceramides and disease provides a more holistic view of the response to treatment. Additionally, it appears that ceramide profiling is able to detect super responders, patients with a strong or early response to treatment (94), as two subjects show a normalized ceramide profile already after 4 weeks. The ability to define a strong response through ceramide profiling might therefore highlight ceramide profiling as a suitable alternative that may be employed to predict the long-term efficacy of a chosen therapy and enable a precision medicine approach (95).

CONCLUSION

In this study, we show that guselkumab therapy normalizes the ceramide profile and alleviates barrier dysfunction in psoriasis patients. Correlations between the ceramide profile and barrier function during the effective clinical response toward guselkumab, but not placebo, underline their interdependency and establish their relationship with disease severity. Ceramide

profiling might represent a suitable biomarker for treatment monitoring. Variation in the study is controlled by matching the controls with patients for approximate age, sex, assessment location, and recruitment throughout seasons. Robustness of the results is underlined by low variation in the placebo group over the 16-weeks treatment period.

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request. 

Supplemental data

This article contains [supplemental data](#) (12, 25, 29, 35).

Acknowledgments

The investigators are grateful to the participating patients and patient association Psoriasispatiënten Nederland and the trial network CONNECTED. Additionally, the investigators want to express their gratitude to Evonik (Essen, Germany) for donating the ceramide standards used in this study.

Author contributions

J. R., C. M., M. E. B., L. J. B., M. L. d. K., N. B. K., T. N.-v. d. K., M. B. A. v. D., J. A. B., and R. R. writing–review and editing; J. R. and C. M. writing–original draft; J. R., C. M., and L. J. B. visualization; J. R., C. M., M. E. B., M. L. d. K., T. v. d. K., J. A. B., and R. R. methodology; J. R., C. M., M. E. B., and M. E. B. investigation; J. R., C. M., L. J. B., and M. L. d. K. formal analysis; J. R., C. M., M. B. A. v. D., J. A. B., and R. R. conceptualization; J. R., C. M., and L. J. B. data curation; N. B. K., T. v. d. K., M. B. A. v. D., J. A. B., and R. R. supervision; M. B. A. v. D. and R. R. funding acquisition.

Author ORCIDs

Jannik Rousel  <https://orcid.org/0000-0003-0986-3753>
Catherine Mergen  <https://orcid.org/0000-0003-2509-6814>
Lisa J. Bruijninx  <https://orcid.org/0009-0004-5656-2800>
Martijn B.A. van Doorn  <https://orcid.org/0000-0003-1672-7899>
Robert Rissmann  <https://orcid.org/0000-0002-5867-9090>

Funding and additional information

CHDR funded this investigator-initiated trial. Janssen-Cilag B.V. provided the medication for use in the clinical study and was involved in the approval of the study protocol. This study is part of the SKINERGY PP trial under NWA-ORC project NWA.1389.20.182 entitled Next Generation ImmunoDermatology (NGID).

Conflict of interest

Dr van Doorn has received consulting fees or honorarium from Novartis, AbbVie, Pfizer, LEO pharma, Sanofi, Lilly, Janssen, and Celgene and grant and payment for lectures including service on speakers bureaus from Novartis, Sanofi, and Janssen outside the submitted work. The other authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations

AD, atopic dermatitis; CCL, ceramide chain length; DES, desaturase; IL, interleukin; LSS, lesion severity score; MUCer, monounsaturated ceramide; PASI, psoriasis area and severity score; SC, stratum corneum; TEWL, trans-epidermal water loss.

Manuscript received April 24, 2024, and in revised form June 15, 2024. Published, JLR Papers in Press, July 9, 2024, <https://doi.org/10.1016/j.jlr.2024.100591>

REFERENCES

- van den Reek, J. M., van Lüumig, P. P., Otero, M. E., Zweegers, J., van de Kerkhof, P. C., Ossenkoppele, P. M., et al. (2014) Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network. *Br. J. Dermatol.* **170**, 1158–1165
- Elias, P. M., Arbiser, J., Brown, B. E., Rossiter, H., Man, M. Q., Cerimele, F., et al. (2008) Epidermal Vascular Endothelial Growth factor production is Required for permeability barrier homeostasis, dermal Angiogenesis, and the development of epidermal hyperplasia: Implications for the pathogenesis of psoriasis. *Am. J. Pathol.* **173**, 689–699
- Nosbaum, A., Dahel, K., Goujon, C., Nicolas, J. F., Mengeaud, V., and Vocanson, M. (2021) Psoriasis is a disease of the entire skin: non-lesional skin displays a prepsoriasis phenotype. *Eur. J. Dermatol.* **31**, 143–154
- Bergboer, J. G. M., Zeeuwen, P. L. J. M., and Schalkwijk, J. (2012) Genetics of psoriasis: evidence for Epistatic Interaction between skin barrier abnormalities and immune Deviation. *J. Invest. Dermatol.* **132**, 2320–2331
- Pershing, L. K., Bakhtian, S., Wright, E. D., and Rallis, T. M. (1995) Differentiation of involved and uninvolved psoriatic skin from healthy skin using noninvasive visual, colorimeter and evaporimeter methods. *Skin Res. Technol.* **1**, 140–144
- Takahashi, H., Tsuji, H., Minami-Hori, M., Miyauchi, Y., and Iizuka, H. (2014) Defective barrier function accompanied by structural changes of psoriatic stratum corneum. *J. Dermatol.* **41**, 144–148
- Proksch, E., Brandner, J. M., and Jensen, J. M. (2008) The skin: an indispensable barrier. *Exp. Dermatol.* **17**, 1063–1072
- Bouwstra, J. A., Nädäban, A., Bras, W., McCabe, C., Bunge, A., and Gooris, G. S. (2023) The skin barrier: an extraordinary interface with an exceptional lipid organization. *Prog. Lipid Res.* **92**, 101252
- Kawana, M., Miyamoto, M., Ohno, Y., and Kihara, A. (2020) Comparative profiling and comprehensive quantification of stratum corneum ceramides in humans and mice by LC/MS/MS. *J. Lipid Res.* **61**, 884
- Rousel, J., Mergen, C., Schoones, J. W., Niemeyer-van der Kolk, T., van Doorn, M. B. A., Bouwstra, J. A., et al. (2024) Similar alterations of the stratum corneum ceramide profile in atopic dermatitis, psoriasis and ichthyosis: results from a systematic review and meta-analysis. *J. Invest. Dermatol.* **S0022-202X**, 00168–00174
- Van Smeden, J., Janssens, M., Vreeken, R., Lavrijsen, A., and Bouwstra, J. (2013) Free fatty acids and lipid chain length correlate with the impaired skin barrier of atopic eczema patients. *J. Invest. Dermatol.* **133**, S123
- Janssens, M., van Smeden, J., Gooris, G. S., Bras, W., Portale, G., Caspers, P. J., et al. (2012) Increase in short-chain ceramides correlates with an altered lipid organization and decreased barrier function in atopic eczema patients. *J. Lipid Res.* **53**, 2755
- Janssens, M., Smeden, J. V., Gooris, G., Bras, W., Portale, G., Caspers, P., Kezic, S., Lavrijsen, S., Bouwstra, J., et al. (2012) Non-lesional skin in atopic eczema patients shows a change in lipid organization that correlates with a decreased barrier function. *J. Invest. Dermatol.* **132**, S77
- Van Smeden, J., Danso, L., Janssens, M., Vreeken, R., Ghalbzouri, A. el, Lavrijsen, S., et al. (2015) Lipid chain length reduction correlates with the skin barrier function in atopic eczema patients and inflammation plays a role in the altered epidermal lipid biosynthesis. *J. Invest. Dermatol.* **135**, S59
- Tawada, C., Kanoh, H., Nakamura, M., Mizutani, Y., Fujisawa, T., Banno, Y., et al. (2014) Interferon- γ decreases ceramides with long-chain fatty acids: Possible involvement in atopic dermatitis and psoriasis. *J. Invest. Dermatol.* **134**, 712–718
- Danso, M. O., van Drongelen, V., Mulder, A., van Esch, J., Scott, H., van Smeden, J., et al. (2014) TNF- α and Th2 cytokines induce atopic dermatitis-like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents. *J. Invest. Dermatol.* **134**, 1941–1950
- Orsmond, A., Bereza-Malcolm, L., Lynch, T., March, L., and Xue, M. (2021) Skin barrier dysregulation in psoriasis. *Int. J. Mol. Sci.* **22**, 10841
- Hawkes, J. E., Chan, T. C., and Krueger, J. G. (2017) Psoriasis pathogenesis and the development of novel, targeted immune therapies. *J. Allergy Clin. Immunol.* **140**, 645
- Puig, L., Daudén, E., Cuervas-Mons, M., Novella, C., and Guisado, C. (2023) Persistence and effectiveness of guselkumab treatment in patients with moderate-to-severe plaque psoriasis in a non-interventional real-world setting: the SPRING study. *J. Eur. Acad. Dermatol. Venereol.* **00**, 1–11
- Reich, K., Armstrong, A. W., Foley, P., Song, M., Wasfi, Y., Randazzo, B., et al. (2017) Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. *J. Am. Acad. Dermatol.* **76**, 418–431
- Takahashi, T., Koga, Y., and Kainoh, M. (2018) Anti-IL-12/IL-23p40 antibody ameliorates dermatitis and skin barrier dysfunction in mice with imiquimod-induced psoriasis-like dermatitis. *Eur. J. Pharmacol.* **828**, 26–30
- Kim, B. K., Shon, J. C., Seo, H. S., Liu, K. H., Lee, J. W., Ahn, S. K., et al. (2022) Decrease of ceramides with long-chain fatty acids in psoriasis: Possible inhibitory effect of interferon gamma on chain elongation. *Exp. Dermatol.* **31**, 122–132
- Uchino, T., Kamiya, D., Yagi, H., Fujino-Shimaya, H., Hatta, I., Fujimori, S., et al. (2023) Comparative analysis of intercellular lipid organization and composition between psoriatic and healthy stratum corneum. *Chem. Phys. Lipids.* **254**, 105305
- Motta, S., Monti, M., Sesana, S., Mellesi, L., Ghidoni, R., and Caputo, R. (1994) Abnormality of water barrier function in psoriasis. Role of ceramide fractions. *Arch. Dermatol.* **130**, 452–456
- Boiten, W., Absalah, S., Vreeken, R., Bouwstra, J., and van Smeden, J. (2016) Quantitative analysis of ceramides using a novel lipidomics approach with three dimensional response modelling. *Biochim. Biophys. Acta.* **1861**, 1652–1661
- Ashcroft, D. M., Li Wan Po, A., Williams, H. C., and Griffiths, C. E. M. (1999) Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. *Br. J. Dermatol.* **141**, 185–191
- Visser, W. H. P. M., Van Vlijmen, I., Van Erp, P. E. J., De Jong, E. M. G. J., and Van De Kerkhof, P. C. M. (2008) Topical treatment of mild to moderate plaque psoriasis with 0.3% tacrolimus gel and 0.5% tacrolimus cream: the effect on SUM score, epidermal proliferation, keratinization, T-cell subsets and HLA-DR expression. *Br. J. Dermatol.* **158**, 705–712
- Glatt, S., Helmer, E., Haier, B., Strimenopoulou, F., Price, G., Vajjah, P., et al. (2017) First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. *Br. J. Clin. Pharmacol.* **83**, 991–1001
- Bakdash, J. Z., and Marusich, L. R. (2017) Repeated measures correlation. *Front. Psychol.* **8**, 252904
- Rousel, J., Bergmans, M. E., Bruijninx, L. J., Lin, S., Niemeyer-van der Kolk, T., Bohoslavsky, R., et al. (2024) Mild Psoriasis Patients are Suitable Alternatives for Moderate-To-Severe Psoriasis Patients in Early-Phase Clinical Trials: Results of a Randomized Controlled Trial with Guselkumab. Submitted
- Rousel, J., Bergmans, M. E., van der Meulen, L. W. J., Pagan, L., de Bruin, D. T., de Kam, M. L., et al. (2023) Guselkumab induction therapy demonstrates long-lasting efficacy in patients with mild psoriasis, results from a randomized, placebo-controlled exploratory clinical trial. *J. Am. Acad. Dermatol.* **90** (2), 395–397
- Rousel, J., Nädäban, A., Saghari, M., Pagan, L., Zhuparris, A., Theelen, B., et al. (2023) Lesional skin of seborrheic dermatitis patients is characterized by skin barrier dysfunction and correlating alterations in the stratum corneum ceramide composition. *Exp. Dermatol.* **33**, 1–12

33. Koyano, S., Hatamochi, A., Yamazaki, S., Ishikawa, J., Kitahara, T., Narita, H., *et al.* (2010) Psoriasis patients have abnormal ceramide profile in stratum corneum. *Nishi Nihon J. Dermatol.* **72**, 494–499
34. Kim, B., Shon, J., Liu, K., Hong, S., and Ahn, S. (2017) Changes in fatty acid lengths of ceramides toward shorter chain dominance in human psoriasis skin. *J. Invest. Dermatol.* **137**, S213
35. Motta, S., Monti, M., Sesana, S., Caputo, R., Carelli, S., and Ghidoni, R. (1993) Ceramide composition of the psoriatic scale. *Biochim. Biophys. Acta.* **1182**, 147–151
36. Van Smeden, J., Janssens, M., Boiten, W. A., van Drongelen, V., Furio, L., Vreeken, R. J., *et al.* (2014) Intercellular skin barrier lipid composition and organization in netherton syndrome patients. *J. Invest. Dermatol.* **134**, 1238–1245
37. Boiten, W., van Smeden, J., and Bouwstra, J. (2020) The Cornified Envelope-bound ceramide fraction is altered in patients with atopic dermatitis. *J. Invest. Dermatol.* **140**, 1097–1100.e4
38. Kihara, A. (2016) Synthesis and degradation pathways, functions, and pathology of ceramides and epidermal acylceramides. *Prog. Lipid Res.* **63**, 50–69
39. Del Duca, E., He, H., Liu, Y., Pagan, A. D., David, E., Cheng, J., *et al.* (2023) Inpatient comparison of atopic dermatitis skin transcriptome shows differences between tape-strips and biopsies. *Allergy.* **00**, 1–13
40. Ota, A., Morita, H., Naganuma, T., Miyamoto, M., Jojima, K., Nojiri, K., *et al.* (2023) Bifunctional DEGS2 has higher hydroxylase activity toward substrates with very-long-chain fatty acids in the production of phytosphingosine ceramides. *J. Biol. Chem.* **299**, 104603
41. Yokose, U., Ishikawa, J., Morokuma, Y., Naoe, A., Inoue, Y., Yasuda, Y., *et al.* (2020) The ceramide [NP]/[NS] ratio in the stratum corneum is a potential marker for skin properties and epidermal differentiation. *BMC Dermatol.* **20**, 6
42. Helder, R. W. J., Rousel, J., Boiten, W. A., Gooris, G. S., Nadaban, A., El Ghalbzouri, A., *et al.* (2021) Improved organotypic skin model with reduced quantity of monounsaturated ceramides by inhibiting stearoyl-CoA desaturase-1. *Biochim. Biophys. Acta.* **1866**, 158885
43. Danso, M., Boiten, W., van Drongelen, V., Gmelig Meijling, K., Gooris, G., El Ghalbzouri, A., *et al.* (2017) Altered expression of epidermal lipid bio-synthesis enzymes in atopic dermatitis skin is accompanied by changes in stratum corneum lipid composition. *J. Dermatol. Sci.* **88**, 57–66
44. Varshney, P., Narasimhan, A., Mittal, S., Malik, G., Sardana, K., and Saini, N. (2016) Transcriptome profiling unveils the role of cholesterol in IL-17A signaling in psoriasis. *Sci. Rep.* **6**, 19295
45. Gupta, D. S., Kaul, D., Kanwar, A. J., and Parsad, D. (2010) Psoriasis: crucial role of LXR-alpha RNomics. *Genes Immun.* **11**, 37–44
46. Berdyshev, E., Goleva, E., Bronova, I., Dyjack, N., Rios, C., Jung, J., *et al.* (2018) Lipid abnormalities in atopic skin are driven by type 2 cytokines. *JCI Insight.* **3**, e98006
47. Ito, S., Ishikawa, J., Naoe, A., Yoshida, H., Hachiya, A., Fujimura, T., *et al.* (2017) Ceramide synthase 4 is highly expressed in involved skin of patients with atopic dermatitis. *J. Eur. Acad. Dermatol. Venereol.* **31**, 135–141
48. Pilz, R., Opálka, L., Majcher, A., Grimm, E., Van Maldergem, L., Mihalceanu, S., *et al.* (2022) Formation of keto-type ceramides in palmoplantar keratoderma based on biallelic KDSR mutations in patients. *Hum. Mol. Genet.* **31**, 1105–1114
49. Gaggini, M., Ndreu, R., Michelucci, E., Rocchiccioli, S., and Vassalle, C. (2022) Ceramides as mediators of oxidative stress and inflammation in Cardiometabolic disease. *Int. J. Mol. Sci.* **23**, 2719
50. Fekry, B., Jeffries, K. A., Esmailniakooshkghazi, A., Szulc, Z. M., Knagge, K. J., Kirchner, D. R., *et al.* (2018) C16-ceramide is a natural regulatory ligand of p53 in cellular stress response. *Nat. Commun.* **9**, 1–12
51. Hannun, Y. A., and Obeid, L. M. (2017) Sphingolipids and their metabolism in physiology and disease. *Nat. Rev. Mol. Cell Biol.* **19**, 175–191
52. Farwanah, H., Raith, K., Neubert, R. H., and Wohlrab, J. (2005) Ceramide profiles of the uninvolved skin in atopic dermatitis and psoriasis are comparable to those of healthy skin. *Arch. Dermatol. Res.* **296**, 514–521
53. Yoshida, T., Beck, L. A., and De Benedetto, A. (2022) Skin barrier defects in atopic dermatitis: from old idea to new opportunity. *Allergol. Int.* **71**, 3–13
54. Grice, K., Sattar, H., Baker, H., and Sharratt, M. (1975) The relationship of transepidermal water loss to skin temperature in psoriasis and eczema. *J. Invest. Dermatol.* **64**, 313–315
55. Montero-Vilchez, T., Segura-Fernández-Nogueras, M. V., Pérez-Rodríguez, I., Soler-Gongora, M., Martínez-Lopez, A., Fernández-González, A., *et al.* (2021) Skin barrier function in psoriasis and atopic dermatitis: transepidermal water loss and temperature as useful Tools to assess disease severity. *J. Clin. Med.* **10**, 359
56. Nikam, V., Monteiro, R., Dandakeri, S., and Bhat, R. (2019) Transepidermal water loss in psoriasis: a Case-control study. *Indian Dermatol. Online J.* **10**, 267
57. Suh, D. H., Kwon, T. E., Kim, S. D., Park, S. B., Kwon, O. S., Kim, K. H., *et al.* (2001) Changes of transepidermal water loss (TEWL) in psoriatic plaques during D-PÜVA therapy. *Ann. Dermatol.* **13**, 7–11
58. Gualdi, G., Bruni, M., Giuliani, F., Gisondi, P., and Amerio, P. (2022) Paradoxical effect on epidermal barrier of anti-TNF-alpha treatment for psoriasis. *J. Clin. Aesthet. Dermatol.* **15**, 36
59. Reich, K., Armstrong, A. W., Langley, R. G., Flavin, S., Randazzo, B., Li, S., *et al.* (2019) Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. *Lancet.* **394**, 831–839
60. Piskin, G., Sylva-Steenland, R. M. R., Bos, J. D., and Teunissen, M. B. M. (2006) In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. *J. Immunol.* **176**, 1908–1915
61. Yasue, Y., Ishitsuka, A., Fujine, E., Banno, Y., Kanoh, H., and Seishima, M. (2016) Effects of interferon-gamma on expression of ceramide synthases and elongases of long-chain fatty acids in cultured human keratinocytes. *J. Dermatol. Sci.* **84**, e17–e18
62. Nakajima, K., Terao, M., Takaishi, M., Kataoka, S., Goto-Inoue, N., Setou, M., *et al.* (2013) Barrier Abnormality due to ceramide deficiency leads to psoriasisiform inflammation in a mouse model. *J. Invest. Dermatol.* **133**, 2555–2565
63. ten Bergen, L. L., Petrovic, A., Krogh Aarebrot, A., and Appel, S. (2020) The TNF/IL-23/IL-17 axis—Head-to-head trials comparing different biologics in psoriasis treatment. *Scand. J. Immunol.* **92**, e12946
64. Sawada, E., Yoshida, N., Sugiura, A., and Imokawa, G. (2012) Th1 cytokines accentuate but Th2 cytokines attenuate ceramide production in the stratum corneum of human epidermal equivalents: an implication for the disrupted barrier mechanism in atopic dermatitis. *J. Dermatol. Sci.* **68**, 25–35
65. Uche, L. E., Gooris, G. S., Bouwstra, J. A., and Beddoes, C. M. (2019) Barrier Capability of skin lipid models: effect of ceramides and free fatty acid composition. *Langmuir.* **35**, 15376–15388
66. Nădăban, A., Rousel, J., El Yachoui, D., Gooris, G. S., Beddoes, C. M., Dalglish, R. M., *et al.* (2023) Effect of sphingosine and phytosphingosine ceramide ratio on lipid arrangement and barrier function in skin lipid models. *J. Lipid Res.* **64**, 100400
67. Pullmannová, P., Pavlíková, L., Kováčik, A., Sochorová, M., Školová, B., Slepíčka, P., *et al.* (2017) Permeability and microstructure of model stratum corneum lipid membranes containing ceramides with long (C16) and very long (C24) acyl chains. *Biophys. Chem.* **224**, 20–31
68. Mojumdar, E. H., Kariman, Z., van Kerckhove, L., Gooris, G. S., and Bouwstra, J. A. (2014) The role of ceramide chain length distribution on the barrier properties of the skin lipid membranes. *Biochim. Biophys. Acta.* **1838**, 2473–2483
69. Mojumdar, E. H., Helder, R. W. J., Gooris, G. S., and Bouwstra, J. A. (2014) Monounsaturated fatty acids reduce the barrier of stratum corneum lipid membranes by enhancing the formation of a hexagonal lateral packing. *Langmuir.* **30**, 6534–6543
70. Mieremet, A., Helder, R. W. J., Nadaban, A., Boiten, W. A., Gooris, G. S., El Ghalbzouri, A., *et al.* (2021) Multitargeted approach for the optimization of morphogenesis and barrier formation in human skin equivalents. *Int. J. Mol. Sci.* **22**, 5790
71. Thakoersing, V. S., Gooris, G. S., Mulder, A., Rietveld, M., El Ghalbzouri, A., and Bouwstra, J. A. (2012) Unraveling barrier properties of three different in-House human skin equivalents. *Tissue Eng. Part C Methods.* **18**, 1–11
72. Boer, D. E. C., van Smeden, J., Al-Khakany, H., Melnik, E., van Dijk, R., Absalah, S., *et al.* (2020) Skin of atopic dermatitis patients shows disturbed β -glucocerebrosidase and acid sphingomyelinase activity that relates to changes in stratum corneum lipid

- composition. *Biochim. Biophys. Acta Mol. Cell Biol. Lipids.* **1865**, 158673
73. van Smeden, J., Janssens, M., Kaye, E. C. J., Caspers, P. J., Lavrijsen, A. P., Vreeken, R. J., *et al.* (2014) The importance of free fatty acid chain length for the skin barrier function in atopic eczema patients. *Exp. Dermatol.* **23**, 45–52
 74. Ishikawa, J., Narita, H., Kondo, N., Hotta, M., Takagi, Y., Masukawa, Y., *et al.* (2010) Changes in the ceramide profile of atopic dermatitis patients. *J. Invest. Dermatol.* **130**, 2511–2514
 75. Langley, R. G., and Ellis, C. N. (2004) Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician's global assessment. *J. Am. Acad. Dermatol.* **51**, 563–569
 76. Gourraud, P. A., Le Gall, C., Puzenat, E., Aubin, F., Ortonne, J. P., and Paul, C. F. (2012) Why Statistics Matter: limited inter-Rater Agreement prevents using the psoriasis area and severity index as a Unique determinant of therapeutic decision in psoriasis. *J. Invest. Dermatol.* **132**, 2171–2175
 77. Papp, K. A., Lebwohl, M. G., Kircik, L. H., Pariser, D. M., Strober, B., Krueger, G. G., *et al.* (2021) The Proposed PASI-HD provides more Precise assessment of plaque psoriasis severity in Anatomical regions with a low area score. *Dermatol. Ther. (Heidelb)*. **11**, 1079–1083
 78. Berth-Jones, J., Grotzinger, K., Rainville, C., Pham, B., Huang, J., Daly, S., *et al.* (2006) A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment. *Br. J. Dermatol.* **155**, 707–713
 79. Rissmann, R., Moerland, M., and van Doorn, M. B. A. (2020) Blueprint for mechanistic, data-rich early phase clinical pharmacology studies in dermatology. *Br. J. Clin. Pharmacol.* **86**, 1011
 80. Berdyshev, E., Goleva, E., Bissonnette, R., Bronova, I., Bronoff, A. S., Richers, B. N., *et al.* (2022) Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis. *Allergy*. **77**, 3388–3397
 81. Lee, S. J., Kim, S. E., Shin, K. O., Park, K., and Lee, S. E. (2021) Dupilumab therapy improves stratum corneum Hydration and skin Dysbiosis in patients with atopic dermatitis. *Allergy Asthma Immunol. Res.* **13**, 762
 82. Haidari, W., Pona, A., and Feldman, S. R. (2020) Management of residual psoriasis in patients on biologic treatment. *J. Drugs Dermatol.* **19**, 188–194
 83. Akdeniz, M., Gabriel, S., Lichterfeld-Kottner, A., Blume-Peytavi, U., and Kottner, J. (2018) Transepidermal water loss in healthy adults: a systematic review and meta-analysis update. *Br. J. Dermatol.* **179**, 1049–1055
 84. Peer, R. P., Burli, A., and Maibach, H. I. (2022) Unbearable transepidermal water loss (TEWL) experimental variability: why? *Arch. Dermatol. Res.* **314**, 99–119
 85. Fujiwara, A., Morifuji, M., Kitade, M., Kawahata, K., Fukasawa, T., Yamaji, T., *et al.* (2018) Age-related and seasonal changes in covalently bound ceramide content in forearm stratum corneum of Japanese subjects: determination of molecular species of ceramides. *Arch. Dermatol. Res.* **310**, 729–735
 86. Rogers, J., Harding, C., Mayo, A., Banks, J., and Rawlings, A. (1996) Stratum corneum lipids: the effect of ageing and the seasons. *Arch. Dermatol. Res.* **288**, 765–770
 87. Muizzuddin, N., Hellemans, L., Van Overloop, L., Corstjens, H., Declercq, L., and Maes, D. (2010) Structural and functional differences in barrier properties of African American, Caucasian and East Asian skin. *J. Dermatol. Sci.* **59**, 123–128
 88. Pappas, A., Kendall, A. C., Brownbridge, L. C., Batchvarova, N., and Nicolaou, A. (2018) Seasonal changes in epidermal ceramides are linked to impaired barrier function in acne patients. *Exp. Dermatol.* **27**, 833–836
 89. Ishikawa, J., Shimotoyodome, Y., Ito, S., Miyauchi, Y., Fujimura, T., Kitahara, T., *et al.* (2013) Variations in the ceramide profile in different seasons and regions of the body contribute to stratum corneum functions. *Arch. Dermatol. Res.* **305**, 151–162
 90. Sadowski, T., Klose, C., Gerl, M. J., Wójcik-Maciejewicz, A., Herzog, R., Simons, K., *et al.* (2017) Large-scale human skin lipidomics by quantitative, high-throughput shotgun mass spectrometry. *Sci. Rep.* **7**, 43761
 91. He, H., Bissonnette, R., Wu, J., Diaz, A., Saint-Cyr Proulx, E., Maari, C., *et al.* (2021) Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis. *J. Allergy Clin. Immunol.* **147**, 199–212
 92. He, H., Olesen, C. M., Pavel, A. B., Clausen, M. L., Wu, J., Estrada, Y., *et al.* (2020) Tape-strip Proteomic profiling of atopic dermatitis on dupilumab Identifies minimally Invasive biomarkers. *Front. Immunol.* **11**, 565656
 93. Keurentjes, A. J., Jakasa, I., and Kezic, S. (2021) Research techniques made simple: stratum corneum tape stripping. *J. Invest. Dermatol.* **141**, 1129–1133.e1
 94. Thomas, S. E., Van Den Reek, J. M. P. A., Seyger, M. M. B., and De Jong, E. M. G. J. (2023) How to define a 'super-responder' to biologics in psoriasis studies. *Br. J. Dermatol.* **189**, 621–622
 95. Geifman, N., Azadbakht, N., Zeng, J., Wilkinson, T., Dand, N., Buchan, I., *et al.* (2021) Defining trajectories of response in patients with psoriasis treated with biologic therapies. *Br. J. Dermatol.* **185**, 825–835